Table 2. Frequent, large CD4 T cell epitope responses to anthrax LF domain I–III peptide panel in immune human donors.

Human cohorts	HLA class II						T cell response to anthrax LF domain I–III epitopes, SFC/106 cells
	DR1		DRB3/4/5		DQB1		LF 41–61	LF 101–120	LF 281–300	LF 337–356	LF 417–436	LF 437–456	LF 467–486
Infected donor 2	4	4	53	53	8	8	0	0	345	0	0	0	323
Infected donor 3	4	14	52	53	5	8	0	0	218	0	0	0	0
Infected donor 6	11	13	52	52	6	11	0	0	0	0	0	0	291
Infected donor 7	4	14	52	53	5	4	0	0	227	0	0	0	633
Vaccinee 3	11	13	52	52	6	7	1275	1357	0	1314	1322	1009	0
Vaccinee 4	15	7	51	53	2	6	473	509	0	0	837	451	0
Vaccinee 5	103	17	52	52	2	5	495	0	0	703	0	0	0
Vaccinee 6	1	13	52	52	5	6	0	0	0	0	0	416	0
Vaccinee 8	1	1	-	-	5	5	0	0	0	0	725	0	0
Vaccinee 10	7	15	51	53	2	6	0	423	0	521	0	0	0

Frequent, large CD4 T cell epitope responses to anthrax LF domain I-III peptide panel in immune human donors. Table indicates positive T cell IFNγ ELIspot responses that were seen in 3 or more donors from the human donor cohort described in the Methods, comprising a total of 9 donors in the cutaneous anthrax (Kayseri) group and 10 donors in the AVP vaccinees (UK) group.